๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Hangzhou
Clinical trial register · China

Clinical Trials in Hangzhou, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Second Affiliated Hospital, Zhejiang University, School of Medicine373 Zhejiang University104 First Affiliated Hospital of Zhejiang University103 AstraZeneca76 Zhejiang Cancer Hospital63
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Hangzhou

1812 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations
NCT06581432Solid Tumours
Boehringer Ingelheim
Phase 2
588
Beijing, Changsha, Hangzhou, Hefei, Nanchang, Nanjing, Shanghai, Wuhan
2024-10-11
Active, closed
Immune Cell Subsets in SLE Patients Treated with Telitacicept
NCT06677801Systemic Lupus Erythematosus (SLE)
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 4
50
Hangzhou
2024-10-11
Recruiting
A Study on the Efficacy and Safety of Oral All-trans Retinoic Acid Combined With Toripalimab in TNBC.
NCT06371274Triple-negative Breast Cancer
First Affiliated Hospital of Zhejiang University
Not applicable
29
Hangzhou
2024-10-10
Recruiting
Coronary CT-Derived FFR-Guided Strategy Versus Medical Therapy
NCT05824520Coronary Artery Disease, Myocardial Ischaemia
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
1,066
Hangzhou
2024-10-10
Recruiting
Neoadjuvant Chemotherapy Combined With Toripalimab for TNBC (NEOTORCH-BREAST02)
NCT06682195TNBC, Triple Negative Breast Cancer
First Affiliated Hospital of Zhejiang University
Phase 2
35
Nanchang, Hangzhou, Harbin, Hefei, Jinhua, Nantong, Shanghai, Shanxi
2024-10-09
Recruiting
Smoking Cessation Program With CBT and Mindfulness Audio Support: A Randomized Controlled Trial
NCT06901713Smoking Cessation; Tobacco Dependence
Sir Run Run Shaw Hospital
Not applicable
2,000
Hangzhou
2024-10-09
Recruiting
Two Types of Single-use Flexible Ureteroscopies for the Treatment of Upper Urinary Tract Stones in Children
NCT06628765Urinary Stone
The Children's Hospital of Zhejiang University School of Medicine
Not applicable
52
Hangzhou
2024-10-08
Recruiting
ARTEMIS-102: HS-20093 Combinations in Patients with Advanced Metastatic Colorectal Cancer
NCT06825624Metastatic Colorectal Cancer (CRC)
Hansoh BioMedical R&D Company
Phase 1
560
Hangzhou
2024-10-03
Recruiting
Phase II Clinical Study of Befotertinib in EGFR Non-classical Mutant NSCLC
NCT06863506NSCLC (Non-small Cell Lung Cancer)
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
78
Hangzhou
2024-10-01
Not yet open
Semi-elemental Versus Polymeric EEN in the Preoperative Optimization for Patients with CD
NCT06587178Crohn Disease, Nutrition Disorders, Surgery
Wei Zhou
Not applicable
304
Hangzhou
2024-10-01
Not yet open
Evaluating the Benefits of Personalized Traditional Chinese Medicine in Postoperative Treatment for Locally Advanced Colorectal Cancer
NCT06596343Locally Advanced Colorectal Cancer, Postoperative Adjuvant Therapy
Sir Run Run Shaw Hospital
Phase 2
80
Hangzhou
2024-10
Not yet open
A Relative Bioavailability and Food Effect Study of HDM1002 in Healthy Subjects
NCT06608329Healthy Adult Subject
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Phase 1
33
Hangzhou
2024-10
Not yet open
Node-Sparing Short-Course Radiation With CAPOX and Sintilimab for MSS Locally Advanced Colon Cancer: A Randomized, Prospective, Multicenter Study
NCT06594692Microsatellite Stable (MSS) Colon Cancer, Locally Advanced Colon Cancer
Sir Run Run Shaw Hospital
Phase 2
140
Hangzhou
2024-10
Active, closed
Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Adizutecan (ABBV-400) Moves Through the Body of Adult Participants With Unresectable Locally Advanced/Metastatic Colorectal Cancer
NCT06464692Colorectal Cancer
AbbVie
Phase 1
31
Beijing, Guangzhou, Harbin, Zhengzhou, Wuhan, Nanchang, Shenyang, Hangzhou
2024-09-30
Recruiting
Exploration of Gender Differences in Liver Aging
NCT06591897Healthy Population
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
18
Hangzhou
2024-09-27
Recruiting
Study of Atrial Fibrillation Combined with Atrial Functional Mitral Regurgitation
NCT06630936Atrial Fibrillation (AF), Atrial Functional Mitral Regurgitation
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
500
Hangzhou
2024-09-27
Recruiting
A Clinical Study to Evaluate the Safety and Efficacy of LY-M003 Injection in Patients With Wilson Disease
NCT06650319Wilson Disease
Chaohui Yu
Phase EARLY_PHASE1
18
Hangzhou
2024-09-24
Recruiting
Assessment of CT-FFR in Patients With CCS: A Prospective Multicenter Cohort Study
NCT07659119Coronary Artery Disease
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
3,000
Hangzhou
2024-09-23
Not yet open
Prediction of Stroke Risk in Patients with Atrial Fibrillation Based on Chest CT Images
NCT06611995Atrial Fibrillation (AF), Ischemic Stroke
First Affiliated Hospital of Zhejiang University
Observational
1,500
Hangzhou
2024-09-23
Recruiting
The Efficacy and Safety of Combining Probiotic VSL#3 With Vedolizumab for the Treatment of Moderate Ulcerative Colitis
NCT06609447Ulcerative Colitis
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 4
100
Beijing, Chongqing, Guangzhou, Wuhan, Xiโ€™an, Chengdu, Hangzhou, Huzhou
2024-09-21
Recruiting
Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
NCT06469944Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms, Esophageal Cancer
Merck Sharp & Dohme LLC
Phase 1/2
160
Beijing, Fuzhou, Xiamen, Zhengzhou, Nanchang, Shanghai, รœrรผmqi, Hangzhou
2024-09-20
Recruiting
Blinatumomab for CNI-Resistant/Intolerant SRNS in Children
NCT06607991CNI-resistant Steriod Resistant Nephrotic Syndrome, CNI-intolerent, Steriod Resistant Nephrotic Syndrome, Multidrug Resistant Nephrotic Syndrome
The Children's Hospital of Zhejiang University School of Medicine
Phase 1
6
Hangzhou
2024-09-19
Recruiting
Different Intraoperative Blood Pressure Management on Postoperative Cognitive Function in Tumor Patients๏ผˆPRECISION๏ผ‰
NCT06711432Tumor, Stroke
Zhejiang Cancer Hospital
Not applicable
214
Hangzhou
2024-09-18
Recruiting
A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
NCT06542250B-cell Malignancies
AstraZeneca
Phase 1/2
174
Hangzhou, Shanghai
2024-09-18
Recruiting
A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease
NCT06572384Lung Diseases, Interstitial
GlaxoSmithKline
Phase 3
440
Beijing, Chengdu, Guangzhou, Hangzhou, Mianyang, Nanjing, Nanning, Shanghai
2024-09-11
Active, closed
Validation of a Model for Predicting Duodenal Stump Leakage After Gastrectomy
NCT06807372Gastric Cancers
Jichao Qin
Observational
1,200
Hangzhou
2024-09-11
Active, closed
Effect Evaluation of Different Blood Products Infusion on Neonatal Anemia
NCT06285604Neonatal Anemia
Women's Hospital School Of Medicine Zhejiang University
Observational
200
Hangzhou
2024-09-10
Recruiting
Pediatric Intravenous Contrast-Enhanced Ultrasound(CEUS) in China
NCT07113808Abdominal Neoplasm, Abdominal Injury, Ascites
The Children's Hospital of Zhejiang University School of Medicine
Observational
108
Hangzhou
2024-09-10
Recruiting
Safety and Effectiveness Study of DragonFly-T System for Severe Tricuspid Regurgitation
NCT05556460Tricuspid Regurgitation
Hangzhou Valgen Medtech Co., Ltd
Not applicable
236
Chengdu, Hangzhou
2024-09-03
Recruiting
Long-Term Safety and Efficacy of HB0034 in Subjects With Generalized Pustular Psoriasis
NCT06477536Generalized Pustular Psoriasis
Shanghai Huaota Biopharmaceutical Co., Ltd.
Phase 2/3
33
Beijing, Hangzhou
2024-09-02
Active, closed
Different Amounts of Moxibustion in the Treatment of DPN: A Clinical RCT Study
NCT06330233Diabetic Peripheral Neuropathy, Pain, Moxibustion, Randomized Controlled Trial
Zhejiang Chinese Medical University
Not applicable
90
Hangzhou
2024-09-01
Recruiting
the Effect of Nutrition-optimized Prehabilitation on Perioperative Intervention in Primary Liver Carcinoma
NCT06549829Hepatocellular Carcinoma, Liver Carcinoma, Hepatobiliary Cancers
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
120
Hangzhou
2024-09-01
Recruiting
Transthoracic vs Transbronchial Cryoablation for Early-stage Peripheral Lung Cancer
NCT06572540Lung Cancer
Jiayuan Sun
Not applicable
110
Guangzhou, Zhengzhou, Shanghai, Chengdu, Hangzhou
2024-09-01
Recruiting
Chemotherapy Combined with Immunotherapy and Targeted Therapy in Cholangiocarcinoma
NCT06718257Cholangiocarcinoma
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
300
Hangzhou
2024-09-01
Not yet open
Research on Key Technologies for Risk Prediction and Precise Diagnosis and Treatment of AIS Based on Epigene-phenotype
NCT06506227Adolescent Idiopathic Scoliosis
The First Affiliated Hospital of Zhejiang Chinese Medical University
Not applicable
2,000
Hangzhou
2024-09-01
Recruiting
Disitamab Vedotin Plus Trastuzumab in Patients With HER2 Positive GC/GEJ Patiens
NCT06572319HER2-positive Gastric Cancer, HER2-positive Gastroesophageal Junction Adenocarcinoma
Zhejiang Cancer Hospital
Phase 1/2
35
Hangzhou
2024-09-01
Recruiting
Randomized Phase II Trial: Chest Wall RT Omission After Prosthetic Reconstruction
NCT06464913Breast Neoplasms
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
152
Hangzhou
2024-09-01
Recruiting
Prospective Observational Cohort Study of Moderate Aortic Valve Disease
NCT06595992Moderate Aortic Valve Stenosis, Moderate Aortic Valve Regurgitation, Aortic Valve Disease
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
1,000
Hangzhou
2024-09-01
Recruiting
Study on the Classification of Comprehensive Treatment Effect of Hepatocellular Carcinoma
NCT06542796Hepatocellular Carcinoma, Immunotherapy
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
100
Hangzhou
2024-09-01
Recruiting
Stereotactic Body Radiotherapy for Oligo-Progression Metastatic Non-Small Cell Lung Cancer
NCT06523673Metastatic Non-Small Cell Lung Cancer, NSCLC Stage IV, OligoProgressive Metastatic Disease
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 3
104
Hangzhou
2024-09
Active, closed
A Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers.
NCT06116136MSI-H/dMMR Gastroesophageal-junction Cancer, MSI-H/dMMR Gastric Cancer
Servier Bio-Innovation LLC
Phase 1/2
48
Beijing, Harbin, Zhengzhou, Shenyang, Jinan, Shanghai, Hangzhou
2024-08-31
Active, closed
Phase IIa Study Evaluating AZD7798 in Crohn's Disease
NCT06450197Moderate to Severe Crohn's Disease
AstraZeneca
Phase 2
120
Beijing, Chengdu, Guangzhou, Hangzhou, Nanchang, Nanjing, Wuhan
2024-08-28
Active, closed
Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)
NCT06486441Endometrial Cancer
Gilead Sciences
Phase 3
640
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangxi Zhuang Autonomous Region, Guangzhou, Hangzhou
2024-08-28
Active, closed
ARISE-A Chinese Real-world Study of Rimegepant for the Acute Treatment of Migraine
NCT06439628Migraine
Chinese PLA General Hospital
Observational
3,000
Beijing, Hangzhou
2024-08-27
Active, closed
Volrustomig Priming Regimens Exploratory Phase II Platform Study
NCT06448754Non-small Cell Lung Cancer
AstraZeneca
Phase 2
194
Beijing, Hangzhou, Jinan, Yantai, Zhengzhou
2024-08-27
Active, closed
GR1803 Injection in Patients With Relapsed/Refractory Multiple Myeloma
NCT06566547Multiple Myeloma
Genrix (Shanghai) Biopharmaceutical Co., Ltd.
Phase 2
116
Hangzhou
2024-08-26
Recruiting
Comparison of Stent-Related Symptoms Between Anti-Reflux Stents and Standard DJ Stents in Children With Urolithiasis
NCT06569173Urolithiasis, Child, Only
The Children's Hospital of Zhejiang University School of Medicine
Not applicable
108
Hangzhou
2024-08-23
Recruiting
A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
NCT06290141Chronic Inflammatory Demyelinating Polyneuropathy
Sanofi
Phase 3
160
Beijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Jiazhuang, Jinan
2024-08-21
Active, closed
Clinical Effectiveness of Non-contact Heart Rate and Respiratory Rate Monitoring System
NCT06573203Sleep, Infant๏ผŒnewborn, Vital Signs
The Children's Hospital of Zhejiang University School of Medicine
Not applicable
70
Hangzhou
2024-08-21
Recruiting
Tislelizumab Combined with Nab-Paclitaxel for First-Line Treatment of Advanced Triple-Negative Breast Cancer with Bone Metastasis๏ผŒan Exploratory, Single-Arm, Multicenter Phase II Clinical Study
NCT06538896Triple-negative Breast Cancer, Bone Metastases
Zhejiang Cancer Hospital
Phase 2
20
Hangzhou
2024-08-20
Active, closed
Evaluate the Efficacy and Safety of Xianglei Tangzu Gao for the Treatment of Wagner Grade II Diabetic Foot Ulcers
NCT06531512Diabetic Foot Ulcer
Oneness Biotech Co., Ltd.
Phase 2/3
120
Jiangmen, Luoyang, Suzhou, Zhenjiang, Shenyang, Xi'an, Hangzhou, Guangzhou
2024-08-16
Recruiting
Blinatumomab Plus Venetoclax Sequenced With Inotuzumab Ozogamicin in Treating B-ALL
NCT06554626Precursor B-Cell Lymphoblastic Leukemia
First Affiliated Hospital of Zhejiang University
Phase 2
20
Hangzhou
2024-08-15
Not yet open
Research of the Application of Artificial Intelligence Model "PANDA"
NCT06528223Pancreatic Cancer
Zhejiang University
Not applicable
200,000
Hangzhou
2024-08-15
Recruiting
Study of Therapeutic Efficacy of CAR-T Cell Therapy in Patients With MDR-SRNS
NCT06553898Multi-Drug Resistant Nephrotic Syndrome, CAR-T Cell Therapy
The Children's Hospital of Zhejiang University School of Medicine
Phase 1
18
Hangzhou
2024-08-13
Recruiting
Bolt CSP-M Holter Study
NCT06540521Heart Failure, Bradycardia
Medtronic Cardiac Rhythm and Heart Failure
Observational
75
Shanghai, Hangzhou
2024-08-13
Recruiting
A Study of HDM2005 in Patients With Relapsed/Refractory B-cell Lymphoma and Advanced Solid Tumor
NCT06615193Advanced Solid Tumors, Refractory Lymphoma, Relapsed Hematologic Malignancy
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Phase 1
111
Zhengzhou, Suzhou, Xuzhou, Nanchang, Jinan, Hangzhou, Tianjing
2024-08-12
Recruiting
The Use of Islet Organoids in the Treatment of Pancreatic Surgery-related Diabetes
NCT06415643T3c Diabetes
Zhejiang University
Not applicable
5
Hangzhou
2024-08-10
Recruiting
Safety and Efficacy of Umbilical Cord-derived Mesenchymal Stem Cell(MSC) Transplantation in the Treatment of Bronchopulmonary Dysplasia(BPD) in Premature Infants
NCT06788470BPD - Bronchopulmonary Dysplasia
The Children's Hospital of Zhejiang University School of Medicine
Phase 1/2
10
Hangzhou
2024-08-09
Recruiting
Adbelimumab Combined With Chemotherapy and Apatinib in Patients With Resectable Esophageal Squamous Cell Carcinoma
NCT06576973Esophageal Squamous Cell Carcinoma, Neoadjuvant Treatment
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
35
Hangzhou
2024-08-08
Recruiting
Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease
NCT06332534Crohn's Disease
AbbVie
Phase 3
110
Beijing, Guangzhou, Zhengzhou, Changsha, Nanchang, Shenyang, Shanghai, Hangzhou
2024-08-08
Recruiting
A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
NCT06549595Untreated Follicular Lymphoma
AstraZeneca
Phase 3
1,018
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou
2024-08-07
Recruiting
Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)
NCT06445972Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms, Esophageal Cancer
Merck Sharp & Dohme LLC
Phase 1/2
210
Beijing, Fuzhou, Xiamen, Zhengzhou, Nanchang, Shanghai, รœrรผmqi, Hangzhou
2024-08-07
Active, closed
Study to Investigate the Efficacy and Safety of Regimens Containing BRII-179, BRII-835, and PEG-IFNฮฑ Treating Chronic Hepatitis B Virus (HBV) Infection (ENRICH)
NCT06491563For Treatment of Chronic Hepatitis B Virus Infection
Brii Biosciences Limited
Phase 2
150
Beijing, Xiamen, Foshan, Guangzhou, Shenzhen, Shanghai, Chengdu, Hangzhou
2024-08-06
Recruiting
A Clinical Study of SPH7485 Tablets in the Treatment of Advanced Solid Tumors.
NCT06487455Advanced Solid Tumor
Shanghai Pharmaceuticals Holding Co., Ltd
Phase 1
170
Changsha, Fuzhou, Hangzhou, Kunming, Shanghai, Wuhan
2024-08-06
Recruiting
A Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma
NCT06371157Hepatocellular Carcinoma
Akeso
Phase 3
469
Zhengzhou, Changsha, Nanjing, Hangzhou
2024-08-02
Not yet open
Early Diagnosis of Pancreatic Cancer Via Deciphering Multi-modal Immunological Signatures
NCT06495749Pancreatic Cancer Resectable
Zhejiang University
Observational
3,000
Hangzhou
2024-08-01
Recruiting
Pucotenlimab Plus Radiotherapy and Chemotherapy for Neoadjuvant Treatment of Locally Advanced Rectal Cance(PUCRT)
NCT06770270Rectal Cancer
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
68
Hangzhou
2024-08-01
Recruiting
A Multicenter, Randomized, Crossover Clinical Trial Study of Digital Intelligence Software in Patients With MAFLD
NCT07233486MAFLD
The Affiliated Hospital of Hangzhou Normal University
Not applicable
2,000
Hangzhou
2024-08-01
Recruiting
A Hierarchical Multi-modal AI Framework for Pathological and Genetic Subtyping of Lung Cancer Based on PET/CT Imaging
NCT07463300Lung Cancer
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
5,500
Guangzhou, Wuhan, Yangzhou, Shenyang, Chengdu, Hangzhou
2024-08-01
By invitation
Evaluation of Clinical Efficacy and Prognosis in Patients With Hypertrophic Obstructive Cardiomyopathy Through Hemodynamic Modeling Reconstructed by CT
NCT06683872Hypertrophic Cardiomyopathy (HCM)
Zhejiang Provincial People's Hospital
Observational
200
Hangzhou
2024-08-01
By invitation
Comparative Study on Changes in Anterior Chamber Cytokines, Oxidative Stress, and Pupil Size After LenSx and Z8 Femtosecond Lasers
NCT06649799Cataract
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
80
Hangzhou
2024-08-01
Recruiting
Comparison Study of EAP and Disease-Specific Chemotherapy Regimens in Hematopoietic Stem Cell Mobilization for Lymphoma
NCT06520163Non-Hodgkin's Lymphoma, Hematopoietic Stem Cell Mobilization
The Affiliated People's Hospital of Ningbo University
Phase 3
99
Dongyang, Hangzhou, Huzhou, Jiaxing, Jinhua, Lishui, Ningbo, Shaoxing
2024-08-01
Recruiting
Efficacy of Ustekinumab Therapy in Patients With Symptomatic Stricturing Crohn's Disease
NCT05387031Crohn Disease, Stricture; Bowel, Intestinal Stricture
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
239
Beijing, Chongqing, Guangzhou, Huai'an, Suzhou, Yangzhou, Hangzhou
2024-08-01
Recruiting
Neoadjuvant ChemoRadiotherapy Followed by Immunotherapy and Surgery for Resectable Esophageal Squamous Cell Carcinoma๏ผˆCRIS-2 Trial๏ผ‰
NCT06509568Esophageal Squamous Cell Carcinoma
Zhejiang Cancer Hospital
Phase 2
92
Hangzhou
2024-08-01
Recruiting
Comparison Study of EAP and CG Regimens for Mobilizing Hematopoietic Stem Cells in Multiple Myeloma Patients
NCT06520176Multiple Myeloma, Hematopoietic Stem Cell Mobilization
The Affiliated People's Hospital of Ningbo University
Phase 3
99
Dongyang, Hangzhou, Huzhou, Jiaxing, Jinhua, Lishui, Ningbo, Shaoxing
2024-08
Recruiting
Phase 2 Study of WGI-0301 for Advanced HCC
NCT06309485Advanced Hepatocellular Carcinoma (HCC)
Zhejiang Haichang Biotech Co., Ltd.
Phase 2
60
Shanghai, Changsha, Chengdu, Hangzhou, Harbin, Nanchang, Wuhan
2024-07-31
Active, closed
SAVE-PCI: NyokAssistโ„ข Small-Bore VAD vs. IABP in Elective High-Risk PCI
NCT07010965High-Risk PCI
magAssist, Inc.
Not applicable
236
Beijing, Changsha, Guangzhou, Hangzhou, Harbin, Lanzhou, Shanghai, Taiyuan
2024-07-31
Recruiting
A Clinical Study of B007 in the Treatment of Primary Membranous Nephropathy.
NCT06470191Primary Membranous Nephropathy
Shanghai Jiaolian Drug Research and Development Co., Ltd
Phase 2/3
216
Beijing, Changchun, Guangzhou, Hangzhou, Jinan, Nanning, Nantong, Qingdao
2024-07-30
Active, closed
Early Combined Use of Dexamethasone Intravitreal Implant and Anti-VEGF in the Treatment of DME.
NCT06846073Diabetic Macular Edema (DME)
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
70
Hangzhou
2024-07-30
Recruiting
Efficacy and Safety of JAK Inhibitors in Patients With AA: RWE Study
NCT06573593Alopecia Areata, Janus Kinase Inhibitors
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
150
Hangzhou
2024-07-29
Recruiting
Adebrelimab Combined With Chemotherapy and Concurrent SBRT for Neoadjuvant Treatment of Limited-stage Small Cell Lung Cancer
NCT06562920Efficacy and Safety of Neoadjuvant Immunotherapy for Small Cell Lung Cancer
Zhejiang Cancer Hospital
Phase 2
20
Hangzhou
2024-07-24
Recruiting
Study of CEA Targeting CAR-T (PTC13) in the Treatment of CEA-Positive Advanced Malignant Solid Tumors
NCT06821048Colorectal Cancer, Stomach Cancer, Pancreatic Cancer, Metastatic Cancer
Weijia Fang, MD
Phase 1
18
Hangzhou
2024-07-24
Recruiting
Prediction of Significant Liver Fibrosis
NCT06509230Liver Fibrosis
Huang Haijun
Observational
700
Hangzhou
2024-07-20
Recruiting
IB/IIa Study of MG-K10 in Adolescent Moderately Severe Patients
NCT06765005Atopic Dermatitis
Shanghai Mabgeek Biotech.Co.Ltd
Phase 1/2
24
Hangzhou
2024-07-19
Recruiting
Cilostazol vs. Aspirin in Acute Non-cardioembolic Stroke With Cerebral mIcrobleeds
NCT06530537Cerebral Microbleeds, Stroke
Zhejiang Provincial People's Hospital
Phase 3
848
Hangzhou
2024-07-18
Recruiting
A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)
NCT06413654Neuromyelitis Optica Spectrum Disorders
Shanghai Jiaolian Drug Research and Development Co., Ltd
Phase 2/3
132
Beijing, Cangzhou, Changsha, Chengdu, Fuzhou, Guangzhou, Guiyang, Hangzhou
2024-07-17
Recruiting
A Clinical Study of SPH5030 Tablets in the Treatment of Her2-positive/Mutated Biliary Tract OR Colorectal Cancer Patients.
NCT06434597Biliary Tract or Colorectal Cancer With Her2-positive/Mutated
Shanghai Pharmaceuticals Holding Co., Ltd
Phase 2
60
Beijing, Changsha, Changzhi, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei
2024-07-17
Recruiting
RIC Allo-HSCT vs. Venetoclax-Based Consolidation in Elderly AML Patients After First CR
NCT06571825Acute Myeloid Leukemia
He Huang
Phase 4
118
Hangzhou
2024-07-17
Recruiting
Milaberon in Advanced Solid Tumors: an Open, Multicenter Clinical Study
NCT06534762NSCLC, SCLC, Colorectal Cancer, Pancreas Cancer
Zhejiang Provincial People's Hospital
Phase 2
260
Hangzhou
2024-07-15
Active, closed
A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not Work
NCT06290128Chronic Inflammatory Demyelinating Polyradiculoneuropathy, Polyneuropathy, Inflammatory Demyelinating, Chronic
Sanofi
Phase 3
109
Beijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Jinan, Nanchang
2024-07-12
Recruiting
Cadonilimab Combination Regimen as First-line Treatment for HER2-expressing GC/GEJ Patients
NCT06650332Metastatic HER2 Positive Gastroesophageal Junction Cancer
Zhejiang Cancer Hospital
Phase 1/2
90
Hangzhou
2024-07-10
Recruiting
A Study to Evaluate Comparative Efficacy and Safety of Guselkumab in High-dose and Extended-interval Versus Standard-dose in Chinese Participants of Moderate-to-severe Plaque Psoriasis
NCT07532486Psoriasis
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
400
Hangzhou
2024-07-10
Recruiting
Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen
NCT06127407Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen
Servier Bio-Innovation LLC
Phase 3
136
Guangzhou, Wuhan, Shang'ai, Shanghai, Chengdu, Hangzhou, Beijing
2024-07-09
Recruiting
TGRX-1942 Chinese Phase I for Advanced Solid Tumor And/or Relapsed/Refractory Hematologic Malignancies
NCT06484816Non Small Cell Lung Cancer, Advanced Solid Tumor, Hematologic Malignancy
Shenzhen TargetRx Co., Ltd.
Phase 1
90
Hangzhou
2024-07-08
Recruiting
Mitoxantrone Hydrochloride Liposome in Combination With Cytarabine and Venetoclax Regimen in Newly Diagnosed Elderly AML
NCT06621199Acute Myeloid Leukemia
First Affiliated Hospital of Zhejiang University
Phase 2
42
Hangzhou
2024-07-08
Recruiting
Mitoxantrone Hydrochloride Liposome, Standard-dose of Cytarabine and Venetoclax in the Treatment of R/R AML
NCT06621212Relapsed/Refractory Acute Myeloid Leukaemia, Myeloid Malignancy
First Affiliated Hospital of Zhejiang University
Phase 2
72
Hangzhou
2024-07-05
Active, closed
Study of Efficacy and Safety of Ruxolitinib in Patients With Grade II to IV Steroid-refractory Acute Graft vs. Host Disease
NCT06462469Steroid-refractory Acute Graft Versus Host Disease
Novartis Pharmaceuticals
Phase 4
36
Guangzhou, Zhengzhou, Wuhan, Xian, Hangzhou, Beijing, Taian, Tianjin
2024-07-04
Recruiting
A Study of FZ-AD005 in Patients With Advanced Solid Tumors
NCT06424665Advanced Solid Tumor, SCLC(Small Cell Lung Cancer) or LCNEC (Large Cell Neuroendocrine Carcinoma)
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Phase 1
162
Changsha, Shanghai, Hangzhou
2024-07-03
Recruiting
ctDNA-guided Selection of Adjuvant Chemotherapy Regimens for Elderly Colon Cancer Patients After Surgery: A Single-center, Randomized, Controlled Study
NCT06609551Colon Cancer, Colon Cancer (Stage II &Amp;Amp;Amp; III)
Zhejiang Cancer Hospital
Phase 3
312
Hangzhou
2024-07-03
Recruiting
A Phase IB/II Clinical Study of SHR-9839 for Injection Combined With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors
NCT06474455Advanced Solid Tumors
Shanghai Hengrui Pharmaceutical Co., Ltd.
Phase 1/2
156
Zhengzhou, Hangzhou
2024-07-02
Rows per page Showing 1001–1100 of 1812
Previous 9 10 11 12 13 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/city/hangzhou?page=11

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 1,812 of those studies with a site in Hangzhou.

How many clinical trials are recruiting in Hangzhou?

1,096 of the 1,812 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 300 have not yet opened recruitment, 372 are active but closed to new participants, and 44 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.